Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2024-12-09 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings
2024-12-09 English
S-8 Filing
Regulatory Filings
2024-11-20 English
SC 13G/A Filing
Major Shareholding Notification
2024-11-12 English
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Earnings Release Classification · 99% confidence The document is a press release dated November 5, 2024, announcing that Galapagos NV will present new data from its cell therapy pipeline (GLPG5101 and GLPG5201) at the American Society of Hematology (ASH) Annual Meeting in December 2024. It details the abstracts, presentation times, and provides background information on the company and its technology. This is not a formal regulatory filing like a 10-K or an IR, nor is it a transcript (CT) or a formal earnings release (ER). It is an announcement about upcoming scientific presentations and data releases, which aligns best with an Investor Presentation (IP) or a general announcement. Since it is primarily focused on presenting scientific/clinical data updates intended for investors and the scientific community at a major conference, 'Investor Presentation' (IP) is the most fitting category, even though it is presented as a press release announcing the presentation schedule. It is not a Report Publication Announcement (RPA) because it is announcing *future* presentations, not the publication of a comprehensive report itself. Q2 2024
2024-11-06 Dutch
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Regulatory Filings Classification · 95% confidence The document is an announcement by Galapagos NV detailing the presentation of new clinical data for its cell therapy candidates (GLPG5101 and GLPG5201) at the American Society of Hematology (ASH) Annual Meeting in December 2024. It summarizes the abstracts, presentation times, and provides background information on the company and its technology. This content is characteristic of an Investor Presentation (IP) or a detailed press release summarizing upcoming scientific disclosures, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a simple Report Publication Announcement (RPA). Since it is a detailed presentation of scientific and clinical data intended for investors and the scientific community, 'Investor Presentation' (IP) is the most fitting category, even though it is presented here as text rather than slides. It is not an ER (too detailed, not focused on period financials), not an AR (not an audit report), and not an RPA (it contains the substance, not just a notice that a report is coming).
2024-11-06 English
6-K Filing
Regulatory Filings
2024-11-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.